| URL | https://www.prnewswire.com/news-releases/micron-bi |
| Source | Cision |
| Date Published | 11/16/2023 |
| Company/Division name | Micron Biomedical |
| Parent company | Micron Biomedical |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| Capital investment ($): | 23.6 |
| City reshored to: | Atlanta |
| State(s) reshored to: | GA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Needle-Free Vaccines |
| What domestic positive factors made reshoring more attractive? | Higher productivity, Lead time/Time to market, Manufacturing/engineering joint innovation (R&D) |